oral plasmodium eEF2 inhibitor

Ph. I candidate for malaria treatment

from phenotypic screen & optimization

The Lancet

Merck Institute for Pharmacometrics

Chemical structure of molecule M5717 Merck Institute antimalarial compound

13.   The Merck Institute antimalarial compound, M5717, is the first plasmodium eEF2 inhibitor to reach clinical development, and is a good example of an orally available dibasic compound as well…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: